LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 124

Search options

  1. Article ; Online: Telemedicine Utilization in the COVID-19 Era: Patterns of Care in Community Urology Practice.

    Dowling, Robert A / Zhang, Song / Goldfischer, Evan / Albala, David M / Bart, Alex

    Urology practice

    2024  Volume 11, Issue 3, Page(s) 474–485

    Abstract: Introduction: The acute phase of the COVID-19 pandemic disrupted ambulatory care in the US, and in response telemedicine was adopted rapidly but unevenly across specialties and time. This study examines the utilization of telemedicine in the specialty ... ...

    Abstract Introduction: The acute phase of the COVID-19 pandemic disrupted ambulatory care in the US, and in response telemedicine was adopted rapidly but unevenly across specialties and time. This study examines the utilization of telemedicine in the specialty of urology across a 3-year period (before, during, and after the onset of the pandemic) with the objective of describing patterns, costs, and trends in telemedicine utilization in the specialty.
    Methods: The study data were drawn from the adjudicated claims of 1726 providers in 41 independent (privately owned) practices across the US from March 2019 to February 2022. Encounters were indexed to providers to allow for comparisons of utilization across time. Telehealth adoption was defined as the percentage of encounters eligible for reimbursement by telehealth actually conducted by telehealth.
    Results: A total of 3,630,474 individual patients and 16,130,444 unique encounters were included in our analysis. Telehealth-eligible (evaluation and management) encounters declined sharply from a prepandemic baseline of 262 per provider per month (pppm) to a nadir of 164 pppm in April 2020 (acute phase), but quickly rebounded to 264 pppm by June 2020 (postacute phase). Telehealth adoption among urology providers in this study was 0% prior to March 2020, peaked at 46% in April 2020, and then declined rapidly in the months afterward.
    Conclusions: Telehealth adoption in urology spiked abruptly during the acute phase of the pandemic before declining to a low but stable level above prepandemic baseline. These findings may have implications for the broader role of telemedicine in the delivery of urologic care.
    MeSH term(s) Humans ; COVID-19/epidemiology ; Urology ; Pandemics ; Telemedicine ; Community Health Services
    Language English
    Publishing date 2024-02-07
    Publishing country United States
    Document type Journal Article
    ISSN 2352-0787
    ISSN (online) 2352-0787
    DOI 10.1097/UPJ.0000000000000523
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel

    Offer, Katharine / McGuire, Michael T / Song, Kunchang / Goldfischer, Michael J / Davare, Monika A / Corless, Christopher L / Beadling, Carol / Neff, Tanaya / Cox, Michael C / Govinda Raju, Sandya / Blackman, Samuel C

    JCO precision oncology

    2024  Volume 7, Page(s) e2300065

    MeSH term(s) Child ; Humans ; Biomarkers, Tumor/genetics ; Gene Fusion ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/genetics ; Proto-Oncogene Proteins B-raf/genetics ; Sarcoma/drug therapy ; Sarcoma/genetics ; Sorting Nexins/genetics
    Chemical Substances Biomarkers, Tumor ; BRAF protein, human (EC 2.7.11.1) ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; SNX8 protein, human ; Sorting Nexins ; tovorafenib (ZN90E4027M)
    Language English
    Publishing date 2024-03-25
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2473-4284
    ISSN (online) 2473-4284
    DOI 10.1200/PO.23.00065
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  3. Article ; Online: Urinary Analysis of

    Lotan, Yair / Raman, Jay D / Konety, Badrinath / Daneshmand, Siamak / Schroeck, Florian / Shariat, Shahrokh F / Black, Peter / de Lange, Michel / Asroff, Scott / Goldfischer, Evan / Efros, Mitchell / Chong, Kian Tai / Huang, Eugene / Chua, Hong Liang / Wu, Qing Hui / Yeow, Siying / Lau, Weida / Yong, Jin / Eng, Molly

    The Journal of urology

    2022  Volume 209, Issue 4, Page(s) 762–772

    Abstract: ... for the : Materials and methods: Two multicenter, prospective studies were undertaken in: (1) U.S. patients ...

    Abstract Purpose: Cxbladder tests are urinary biomarker tests for detection of urothelial carcinoma. We developed enhanced Cxbladder tests that incorporate DNA analysis of 6 single nucleotide polymorphisms for the
    Materials and methods: Two multicenter, prospective studies were undertaken in: (1) U.S. patients with gross hematuria aged ≥18 years and (2) Singaporean patients with gross hematuria or microhematuria aged >21 years. All patients provided a midstream urine sample and underwent cystoscopy. Samples were retrospectively analyzed using enhanced Cxbladder-Triage (risk stratifies patients), enhanced Cxbladder-Detect (risk stratifies patients and detects positive patients), and the combination enhanced Cxbladder-Triage × Cxbladder-Detect.
    Results: In the pooled cohort (N=804; gross hematuria: n=484, microhematuria: n=320), enhanced Cxbladder-Detect had a sensitivity of 97% (95% CI 89%-100%), specificity of 90% (95% CI 88%-92%), and negative predictive value of 99.7% (95% CI 99%-100%) for detection of urothelial carcinoma. Overall, 83% of patients were enhanced Cxbladder-Detect-negative (ie, needed no further work-up). Of 133 enhanced Cxbladder-Detect-positive patients, 59 had a confirmed tumor, of which 19 were low-grade noninvasive papillary carcinoma or papillary urothelial neoplasm of low malignant potential. In total, 40 tumors were high-grade Ta, T1-T4, Tis, including concomitant carcinoma in situ. Of the 74 patients with normal cystoscopy, 41 were positive by single nucleotide polymorphism analysis. Enhanced Cxbladder-Triage and enhanced Cxbladder-Detect had significantly better specificity than the first-generation Cxbladder tests (
    Conclusions: This study in ethnically diverse patients with hematuria showed the analytical validity of the enhanced Cxbladder tests.
    MeSH term(s) Humans ; Adolescent ; Adult ; Carcinoma, Transitional Cell/diagnosis ; Carcinoma, Transitional Cell/genetics ; Carcinoma, Transitional Cell/urine ; Urinary Bladder Neoplasms/diagnosis ; Urinary Bladder Neoplasms/genetics ; Urinary Bladder Neoplasms/urine ; Hematuria/etiology ; Hematuria/genetics ; Prospective Studies ; Retrospective Studies ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/urine ; Cystoscopy ; Carcinoma in Situ ; Risk Assessment ; Mutation ; Sensitivity and Specificity ; Receptor, Fibroblast Growth Factor, Type 3/genetics ; Telomerase/genetics
    Chemical Substances Biomarkers, Tumor ; FGFR3 protein, human (EC 2.7.10.1) ; Receptor, Fibroblast Growth Factor, Type 3 (EC 2.7.10.1) ; TERT protein, human (EC 2.7.7.49) ; Telomerase (EC 2.7.7.49)
    Language English
    Publishing date 2022-12-30
    Publishing country United States
    Document type Multicenter Study ; Journal Article
    ZDB-ID 3176-8
    ISSN 1527-3792 ; 0022-5347
    ISSN (online) 1527-3792
    ISSN 0022-5347
    DOI 10.1097/JU.0000000000003126
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui VI Zs.91: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 331: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Peroxisomal diseases: a microscopist looks through the retrospectroscope.

    Goldfischer, S

    Annals of the New York Academy of Sciences

    1996  Volume 804, Page(s) 424–426

    MeSH term(s) History, 20th Century ; Humans ; Peroxisomal Disorders/history ; Zellweger Syndrome/physiopathology
    Language English
    Publishing date 1996-12-27
    Publishing country United States
    Document type Historical Article ; Journal Article ; Review
    ZDB-ID 211003-9
    ISSN 1749-6632 ; 0077-8923
    ISSN (online) 1749-6632
    ISSN 0077-8923
    DOI 10.1111/j.1749-6632.1996.tb18633.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Se 110: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: An Evaluation of Sexual Function in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia in Men Treated with the Temporarily Implanted Nitinol Device.

    Elterman, Dean / Alshak, Mark N / Martinez Diaz, Susana / Shore, Neal / Gittleman, Marc / Motola, Jay / Pike, Sheldon / Hermann, Craig / Terens, William / Kohan, Alfred / Gonzalez, Ricardo / Katz, Aaron / Schiff, Jeffrey / Goldfischer, Evan / Grunberger, Ivan / Tu, Le / Kaminetsky, Jed / Chughtai, Bilal

    Journal of endourology

    2022  Volume 37, Issue 1, Page(s) 74–79

    Abstract: Purpose: ...

    Abstract Purpose:
    MeSH term(s) Aged ; Humans ; Male ; Middle Aged ; Erectile Dysfunction/etiology ; Lower Urinary Tract Symptoms/surgery ; Prostatic Hyperplasia/complications ; Prostatic Hyperplasia/surgery ; Treatment Outcome
    Chemical Substances nitinol (2EWL73IJ7F)
    Language English
    Publishing date 2022-10-03
    Publishing country United States
    Document type Randomized Controlled Trial ; Multicenter Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 356931-7
    ISSN 1557-900X ; 0892-7790
    ISSN (online) 1557-900X
    ISSN 0892-7790
    DOI 10.1089/end.2022.0226
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2628: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 208: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.

    Kim, Edward / Seftel, Allen / Goldfischer, Evan / Baygani, Simin / Burns, Patrick

    Current medical research and opinion

    2015  Volume 31, Issue 2, Page(s) 379–389

    Abstract: Objective: Phosphodiesterase type-5 inhibitors (PDE5Is) are first-line therapies for erectile dysfunction (ED). Sildenafil (SIL) and vardenafil (VAR) are approved for as-needed (PRN) dosing; tadalafil (TAD) is approved for both PRN and once-a-day (OaD) ... ...

    Abstract Objective: Phosphodiesterase type-5 inhibitors (PDE5Is) are first-line therapies for erectile dysfunction (ED). Sildenafil (SIL) and vardenafil (VAR) are approved for as-needed (PRN) dosing; tadalafil (TAD) is approved for both PRN and once-a-day (OaD) dosing for ED. Recent evidence suggests that TAD-OaD may be effective as therapy in men with an incomplete response to PRN-PDE5I therapy. This study evaluated whether TAD-OaD provides similar efficacy in men with ED who had previously demonstrated a partial response to PRN-PDE5I therapy.
    Research design and methods: In this randomized, double-blind, placebo-controlled trial, men with a ≥3 month ED history received SIL 100 mg, TAD 20 mg, or VAR 20 mg during a 4 week open-label lead-in period. Those with International Index of Erectile Function - Erectile Function (IIEF-EF) domain scores <26 following lead-in treatment completed a 4 week washout period, then randomized to TAD 2.5 mg up-titrated to 5 mg, TAD 5 mg, or placebo (PBO) OaD for 12 weeks. MAIN OUTCOME MEASURES obtained from patients treated with TAD-OaD were compared to PBO-treated patients. Additionally, results of treatment with TAD-OaD were compared to results obtained from 4 week PRN-PDE5I therapy to determine whether OaD and PRN regimens provided comparable efficacy.
    Clinical trial registration: NCT01130532.
    Main outcome measures: International Index of Erectile Function (IIEF) domain scores; Sexual Encounter Profile (SEP) questions 2-5.
    Results: Endpoint data was obtained from 590 men (391 TAD; 199 PBO). RESULTS for all IIEF and SEP measures were significantly better for TAD-OaD (p < 0.001 for all) compared to PBO and were comparable to those observed during PRN-PDE5I treatment. TAD 2.5 mg and TAD 5 mg OaD therapy were safe and generally well tolerated.
    Conclusion: Tadalafil once daily is a viable alternative to as-needed PDE5I therapy in men with ED. Key limitations include the lack of a PRN PDE5I study group during the double-blind period, and that many more patients took tadalafil than sildenafil or vardenafil during the PRN period.
    MeSH term(s) Adult ; Carbolines/administration & dosage ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Monitoring/methods ; Erectile Dysfunction/drug therapy ; Erectile Dysfunction/etiology ; Erectile Dysfunction/psychology ; Humans ; Imidazoles/administration & dosage ; Male ; Middle Aged ; Patient Preference ; Phosphodiesterase 5 Inhibitors/administration & dosage ; Piperazines/administration & dosage ; Purines/administration & dosage ; Sildenafil Citrate ; Sulfonamides/administration & dosage ; Sulfones/administration & dosage ; Tadalafil ; Treatment Outcome ; Triazines/administration & dosage ; Vardenafil Dihydrochloride
    Chemical Substances Carbolines ; Imidazoles ; Phosphodiesterase 5 Inhibitors ; Piperazines ; Purines ; Sulfonamides ; Sulfones ; Triazines ; Vardenafil Dihydrochloride (5O8R96XMH7) ; Tadalafil (742SXX0ICT) ; Sildenafil Citrate (BW9B0ZE037)
    Language English
    Publishing date 2015-02
    Publishing country England
    Document type Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 80296-7
    ISSN 1473-4877 ; 0300-7995
    ISSN (online) 1473-4877
    ISSN 0300-7995
    DOI 10.1185/03007995.2014.989317
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 955: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: A 17-gene Panel for Prediction of Adverse Prostate Cancer Pathologic Features: Prospective Clinical Validation and Utility.

    Eggener, Scott / Karsh, Lawrence I / Richardson, Tim / Shindel, Alan W / Lu, Ruixiao / Rosenberg, Steven / Goldfischer, Evan / Korman, Howard / Bennett, John / Newmark, Jay / Denes, Bela S

    Urology

    2019  Volume 126, Page(s) 76–82

    Abstract: Objective: To validate the 17-gene Oncotype DX Genomic Prostate Score (GPS) biopsy-based gene expression assay as a predictor of adverse pathology (AP, Gleason score [pGS] ≥4+3and/or ≥pT3) in a prospectively enrolled cohort.: Methods: Between July ... ...

    Abstract Objective: To validate the 17-gene Oncotype DX Genomic Prostate Score (GPS) biopsy-based gene expression assay as a predictor of adverse pathology (AP, Gleason score [pGS] ≥4+3and/or ≥pT3) in a prospectively enrolled cohort.
    Methods: Between July 2014 and September 2015, 1200 men with very low-, low-, and favorable intermediate-risk prostate cancer enrolled in a multi-institutional prospective study of the GPS assay (NCT03502213). The subset who proceeded to immediate radical prostatectomy (RP) after GPS testing was included in a prespecified subanalysis of GPS on biopsy and its association with surgical AP on RP using logistic regression and receiver operating characteristic curves. The effect of GPS testing on physicians' and patients' attitudes about decision making was assessed with the Decisional Conflict Scale.
    Results: One hundred fourteen patients (treated by 59 physicians from 19 sites) elected RP and 40 (35%) had AP. GPS result was a significant predictor of AP (odds ratio per 20 GPS units [OR/20 units]: 2.2; 95% CI 1.2-4.1; P = .008) in univariable analysis and remained significant after adjustment for biopsy Gleason score, clinical T-stage, and logPSA (OR/20 units: 1.9; 95% CI 1.0-3.8; P = .04), or NCCN risk group (OR/20 units: 2.0; 95% CI 1.1-3.7; P = .02). Mean pre-GPS Decisional Conflict Scale score was 27 (95% CI 24-31), which improved significantly after GPS testing to 14 (95% CI 11-17) (P < .001).
    Conclusion: In this real-world multi-institutional study, the GPS assay was prospectively confirmed as an independent predictor of AP at surgery. GPS testing was associated with reduced patient decisional conflict.
    MeSH term(s) Aged ; Genes, Neoplasm ; Humans ; Male ; Middle Aged ; Neoplasm Grading ; Prognosis ; Prospective Studies ; Prostatic Neoplasms/classification ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/pathology ; Prostatic Neoplasms/therapy ; Risk Assessment
    Language English
    Publishing date 2019-01-03
    Publishing country United States
    Document type Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't ; Validation Studies
    ZDB-ID 192062-5
    ISSN 1527-9995 ; 0090-4295
    ISSN (online) 1527-9995
    ISSN 0090-4295
    DOI 10.1016/j.urology.2018.11.050
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1142: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 275: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial.

    Chughtai, Bilal / Elterman, Dean / Shore, Neal / Gittleman, Marc / Motola, Jay / Pike, Sheldon / Hermann, Craig / Terrens, William / Kohan, Alfred / Gonzalez, Ricardo R / Katz, Aaron / Schiff, Jeffery / Goldfischer, Evan / Grunberger, Ivan / Tu, Le Mai / Alshak, Mark N / Kaminetzky, Jed

    Urology

    2020  Volume 153, Page(s) 270–276

    Abstract: ... decrease in IPSS (P< .0001), a 3.52ml/s increase in peak urinary flow rate (P < .0001) and a 1.9-point ...

    Abstract Objective: To report the results of a multicenter, randomized, controlled trial with a temporarily implanted nitinol device (iTind; Medi-Tate Ltd, Hadera, Israel) compared to sham for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
    Materials and methods: Men 50 years or older were randomized 2:1 between iTind and sham procedure arms. A self-expanding, temporary nitinol device was placed for 5-7 days and an 18F Foley catheter was inserted and removed for the iTind and sham group, respectively. Patients were assessed at baseline, 1.5, 3, and 12 months postoperatively using the IPSS, peak urinary flow rate, residual urine, quality of life, and the International Index of Erectile Function. Unblinding occurred at 3 months.
    Results: A total of 175 men (mean age 61.1 ± 6.5) participated (118 iTind vs 57 sham). A total of 78.6% of patients in the iTind arm showed a reduction of ≥3 points in IPSS, vs 60% of patients in the control arm at 3 months. At 12 months, the iTind group reported a 9.25 decrease in IPSS (P< .0001), a 3.52ml/s increase in peak urinary flow rate (P < .0001) and a 1.9-point reduction in quality of life (P < .0001). Adverse events were typically mild and transient, most Clavien-Dindo grade I or II, in 38.1% of patients in the iTind arm and 17.5% in the control arm. No de novo ejaculatory or erectile dysfunction occurred.
    Conclusion: Treatment with the second-generation iTind provided rapid and sustained improvement in lower urinary tract symptoms for the study period while preserving sexual function.
    MeSH term(s) Alloys ; Humans ; Lower Urinary Tract Symptoms/etiology ; Lower Urinary Tract Symptoms/surgery ; Male ; Middle Aged ; Prospective Studies ; Prostatic Hyperplasia/complications ; Prostheses and Implants ; Single-Blind Method
    Chemical Substances Alloys ; nitinol (2EWL73IJ7F)
    Language English
    Publishing date 2020-12-26
    Publishing country United States
    Document type Journal Article ; Multicenter Study ; Randomized Controlled Trial
    ZDB-ID 192062-5
    ISSN 1527-9995 ; 0090-4295
    ISSN (online) 1527-9995
    ISSN 0090-4295
    DOI 10.1016/j.urology.2020.12.022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1142: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 275: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.

    Chamie, Karim / Chang, Sam S / Kramolowsky, Eugene / Gonzalgo, Mark L / Agarwal, Piyush Kumar / Bassett, Jeffrey C / Bjurlin, Marc / Cher, Michael L / Clark, William / Cowan, Barrett E / David, Richard / Goldfischer, Evan / Guru, Khurshid / Jalkut, Mark W / Kaffenberger, Samuel D / Kaminetsky, Jed / Katz, Aaron E / Koo, Alec S / Sexton, Wade J /
    Tikhonenkov, Sergei N / Trabulsi, Edouard J / Trainer, Andrew F / Spilman, Patricia / Huang, Megan / Bhar, Paul / Taha, Sharif A / Sender, Lennie / Reddy, Sandeep / Soon-Shiong, Patrick

    NEJM evidence

    2022  Volume 2, Issue 1, Page(s) EVIDoa2200167

    Abstract: IL-15 Superagonist NAI in BCG-Unresponsive NMIBCIn this trial, patients with BCG-unresponsive bladder CIS with or without Ta/T1 papillary disease or BCG-unresponsive high-grade Ta/T1 papillary NMIBC were treated with intravesical NAI, an IL-15 ... ...

    Abstract IL-15 Superagonist NAI in BCG-Unresponsive NMIBCIn this trial, patients with BCG-unresponsive bladder CIS with or without Ta/T1 papillary disease or BCG-unresponsive high-grade Ta/T1 papillary NMIBC were treated with intravesical NAI, an IL-15 superagonist, plus BCG. Primary end points were CR at 3 or 6 months for patients with CIS disease and DFS rate at 12 months for those with high-grade Ta/T1 disease. CR rate was 71% (58 of 82 patients), and the DFS rate was 55.4%.
    MeSH term(s) Humans ; BCG Vaccine ; Non-Muscle Invasive Bladder Neoplasms ; Interleukin-15 ; Urinary Bladder Neoplasms/therapy
    Chemical Substances BCG Vaccine ; Interleukin-15
    Language English
    Publishing date 2022-11-10
    Publishing country United States
    Document type Journal Article
    ISSN 2766-5526
    ISSN (online) 2766-5526
    DOI 10.1056/EVIDoa2200167
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  10. Article: The internal reticular apparatus of Camillo Golgi: a complex, heterogeneous organelle, enriched in acid, neutral, and alkaline phosphatases, and involved in glycosylation, secretion, membrane flow, lysosome formation, and intracellular digestion.

    Goldfischer, S

    The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society

    1982  Volume 30, Issue 7, Page(s) 717–733

    Abstract: Its topography is one of the most characteristic features of the Golgi apparatus and the reticular nature of this organelle is evident in Golgi's first drawings, in light microscopic enzyme cytochemical preparations, and in high voltage electron ... ...

    Abstract Its topography is one of the most characteristic features of the Golgi apparatus and the reticular nature of this organelle is evident in Golgi's first drawings, in light microscopic enzyme cytochemical preparations, and in high voltage electron micrographs of thick sections. Although individual components of the Golgi apparatus may differ in staining characteristics, morphology, contents, and enzymatic activities, they are integrated into a dynamic topographical and functional unit that is closely associated with the endoplasmic reticulum. Modulation of enzymatic activities and morphological and enzymatic heterogeneity are not surprising in an organelle that is the site of both synthetic and digestive events, including glycosylation, sulfation, formation of secretory granules and lysosomes, and the degradation of endocytized material.
    MeSH term(s) Acid Phosphatase/metabolism ; Alkaline Phosphatase/metabolism ; Animals ; Biological Transport ; Golgi Apparatus/physiology ; Golgi Apparatus/secretion ; Golgi Apparatus/ultrastructure ; Histocytochemistry ; Lysosomes/physiology ; Microscopy, Electron ; Phosphoric Monoester Hydrolases/metabolism ; Rats
    Chemical Substances Alkaline Phosphatase (EC 3.1.3.1) ; Acid Phosphatase (EC 3.1.3.2) ; Phosphoric Monoester Hydrolases (EC 3.1.3.2)
    Language English
    Publishing date 1982-07
    Publishing country United States
    Document type Journal Article ; Research Support, U.S. Gov't, P.H.S. ; Review
    ZDB-ID 218208-7
    ISSN 1551-5044 ; 0022-1554
    ISSN (online) 1551-5044
    ISSN 0022-1554
    DOI 10.1177/30.7.6286754
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uc I Zs.321: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top